Meritage Pharma Inc.
This article was originally published in Start Up
Meritage Pharma was built by serial biotech entrepreneur Cam Garner around a viscous formulation of budesonide designed to coat the inflamed throat. It is now in Phase II trials for an orphan indication, pediatric eosinophilic esophagitis, an inflammation of the esophagus that appears to be triggered by allergies. Meritage's decision to reformulate a compound with a well-established safety record is, like the choice to pursue an orphan drug designation, a risk- and cost-reducing maneuver that has helped other biotech companies achieve success.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Target the GI Tract," features profiles of Alvine Pharmaceuticals, Genetic Analysis, Meritage Pharma and Ventrus Biosciences. Plus these Start-Ups Across Health Care: Advanced Cardiac Therapeutics, Concert Pharmaceuticals, ImThera Medical, On-Q-ity and Telormedix.
A number of diseases are associated with or influenced by imbalances in gut bacteria, including autism and GI disorders such as ulcers, Crohn's disease, inflammatory bowel disease, irritable bowel syndrome, colon cancer, and necrotizing enterocolitis in preterm infants. Many other conditions not obviously associated with the gastrointestinal tract also seem to be influenced by imbalance in the gut, such as allergies, eczema, depression and obesity. Genetic Analysis is developing the G-MAP, a microbiota array technology that analyzes and profiles the gut microflora and associates the resulting profile with various diseases.
Regulatory risk and a mature market for some indications have driven Big Pharma players from the gastrointestinal space. That signals possible biotech opportunity. In this issue, we profile Alvine Pharmaceuticals, Genetic Analysis, Meritage Pharma and Ventrus Biosciences.